Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine ER Rapid Dose Escalation in Alzheimer's Disease
NCT00082602Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2004
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of galantamine in Alzheimer's disease (AD), sponsored by Johnson & Johnson. Started May 2004; status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00082602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082602.